At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...

Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...

AbbVie’s stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company’s Phase II ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...

ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine ...

We explore the immense potential of gamma delta T cells, and the challenges in sourcing and scaling up sufficient volumes to ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

At the Outsourcing in Clinical Trials Conference in New England, experts shared insights on how the US clinical trial and ...

RAPT Therapeutics’ CEO Brian Wong said there was no “viable path forward” for the compound. Image credit: Shutterstock/Andrii Yalanskyi. RAPT Therapeutics has called it quits on a clinical programme ...

The funding is set to support the initiation various trials of its assets. Credit: SOMKID THONGDEE/Shutterstock. Disc Medicine (Disc) has secured a $200m non-dilutive term loan facility from Hercules ...